The first positive Phase 1 clinical data assessing cemiplimab as a potiential treatment for advanced non-small cell lung cancer (NSCLC) will be shared at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Cemiplimab is an investigational human monoclonal antibody targeting the immune checkpoint PD-1 (programmed cell death protein 1).

The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.  Advanced CSCC is the deadliest non-melanoma skin cancer . Cemiplimab is an investigational human monoclonal antibody targeting the checkpoint inhibitor PD-1 (programmed death 1) and was granted Breakthrough Therapy designation status by the FDA in September 2017.

Patients with relapsing remitting multiple sclerosis (RRMS) who received Sanofi Genzyme’s Lemtrada^® (alemtuzumab) experienced effects of treatment on disease activity that were maintained over seven years, according to data from the extension of two pivotal studies. These results will be presented this week during the 70^th annual meeting of the American Academy of Neurology (AAN) in Los Angeles, CA.

Sanofi today announced it will present nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 14-18. Building on its strong heritage in oncology, the company will share new, early-stage studies highlighting an emerging and dynamic portfolio that encompasses diverse strategies, including immuno-oncology (I-O).